Table 2.

Demographic, clinical characteristics, and MRS data of remission and non-remission.

	Remission (25)	Non-remission (10)	P-value
Age, mean ± SD, y	23.48 ± 4.52	19.30 ± 2.58	0.010
Gender (male/female)	14/11	8/2	0.259
Risperidone dose, mean ± SD	3.60 ± 0.50	4.30 ± 0.48	0.001
Education, mean ± SD, y	11.24 ± 2.49	10.60 ± 1.90	0.470
(Baseline)Panss-T	80.68 ± 12.11	94.50 ± 13.55	0.006
(Baseline)Panss-P	21.88 ± 4.71	24.60 ± 6.20	0.168
(Baseline)Panss-N	16.68 ± 3.52	22.60 ± 4.17	<0.001
(Baseline)Panss-G	42.12 ± 8.91	47.30 ± 7.71	0.117
(Week8) Panss-T	53.72 ± 8.27	81.40 ± 9.88	<0.001
(Week8) Panss-P	11.36 ± 2.40	20.40 ± 5.21	<0.001
(Week8) Panss-N	11.88 ± 2.35	19.60 ± 4.25	<0.001
(Week8) Panss-G	30.48 ± 1.16	41.40 ± 5.68	<0.001
ACC-Glu	9.22 ± 1.05	8.17 ± 1.08	0.013
ACC-Glu/Cr+PCr	1.67 ± 0.26	1.53 ± 0.28	0.117

PANSS, Positive and Negative Symptoms Scale; PANSS-T, PANSS total scores; PANSS-P, PANSS positive symptom scores; PANSS-N, PANSS negative symptom scores; PANSS-G, PANSS general psychopathological symptom scores.